Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Agios Pharmaceuticals, Inc. (AGIO) had Normalized Pre-Tax Income of $717.97M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$36.50M |
|
$673.73M |
|
$4.17M |
|
$32.33M |
|
$462.24M |
|
$-425.74M |
|
$1.14B |
|
$717.97M |
|
|
Normalized Pre-Tax Income |
$717.97M |
$673.73M |
|
$673.73M |
|
$673.73M |
|
$673.73M |
|
$-425.74M |
|
$-434.57M |
|
56.81M |
|
57.89M |
|
$11.86 |
|
$11.64 |
|
| Balance Sheet Financials | |
$965.60M |
|
$11.68M |
|
$697.60M |
|
$1.66B |
|
$81.16M |
|
-- |
|
$41.09M |
|
$122.24M |
|
$1.54B |
|
$1.54B |
|
$1.54B |
|
57.16M |
|
| Cash Flow Statement Financials | |
$-389.84M |
|
$363.44M |
|
$14.44M |
|
$88.20M |
|
$76.25M |
|
$-11.96M |
|
$42.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.59% |
|
-1166.47% |
|
-1166.47% |
|
-1190.67% |
|
1967.15% |
|
1845.92% |
|
$-391.49M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
0.15 |
|
8.88 |
|
41.09 |
|
43.72% |
|
43.72% |
|
40.51% |
|
43.72% |
|
$26.96 |
|
$-6.76 |
|
$-6.73 |
|